1 nt was given open-label, but those doing tumour
assessments were masked to treatment assignment.
2 their study partners (generally carers), and all
assessors were masked to treatment assignment throughout the study.
3 All patients, physicians, and outcome
assessors were masked to treatment assignment.
4 Patients, investigators, staff, and outcome
assessors were masked to treatment assignment.
5 Patients, investigators, and
clinicians were masked to treatment assignment.
6 tigators, and individuals who handled and analysed the
data were masked to treatment assignment.
7 igators, and individuals involved in analysis of trial
data were masked to treatment assignment.
8 Investigators, patients, and the
funder were masked to treatment assignment.
9 Patients, investigators, staff, and the
funder were masked to treatment assignment.
10 Patients, medical staff, investigators, and the
funder were masked to treatment assignment.
11 The research team and parents of the
infants were masked to treatment assignment.
12 Patients and
investigators were masked to treatment assignment by the use of unique iden
13 Patients and
investigators were masked to treatment assignment by use of central randomi
14 Patients and
investigators were masked to treatment assignment during the study.
15 Patients and
investigators were masked to treatment assignment.
16 Patients and
investigators were masked to treatment assignment.
17 Patients and
investigators were masked to treatment assignment.
18 Participants and
investigators were masked to treatment assignment.
19 Neither patients nor
investigators were masked to treatment assignment.
20 Patients and study
investigators were masked to treatment assignment.
21 ts and those administering treatment and assessing
outcomes were masked to treatment assignment.
22 All investigators assessing
outcomes were masked to treatment assignment.
23 s, and study personnel, including those assessing
outcomes,
were masked to treatment assignment.
24 All
participants were masked to treatment assignment.
25 Study site staff and
participants were masked to treatment assignment from enrolment through we
26 All study personnel and
participants were masked to treatment assignment.
27 eating physician, clinical research staff, and
participants were masked to treatment assignment.
28 investigators, clinical trial site staff, and
pathologists were masked to treatment assignment throughout the study.
29 Patients were masked to treatment assignment.
30 Investigators and
patients were masked to treatment assignment.
31 Study personnel and
patients were masked to treatment assignment.
32 clinical research organisation, investigators, and
patients were masked to treatment assignment.
33 Patients, study investigators, and study sponsor
personnel were masked to treatment assignment.
34 vestigators assessing outcomes, and sponsor study
personnel were masked to treatment assignment.
35 Patients and study
personnel were masked to treatment assignment.
36 Participants, caregivers, and study
personnel were masked to treatment assignment.
37 andomisation schedule, and all patients and study
personnel were masked to treatment assignment.
38 Participants, clinicians, and trial
personnel were masked to treatment assignment.
39 Participants and care
providers were masked to treatment assignment.
40 Patients and investigators (including local
radiologists)
were masked to treatment assignment from randomisation until
41 cipants and all study staff, including the central
readers,
were masked to treatment assignment apart from the pharmacist
42 Patients, investigators, and the study
sponsor were masked to treatment assignment.
43 ts of participants and clinical, data, and laboratory
staff were masked to treatment assignment.
44 The patients, investigators, and site
staff were masked to treatment assignment.
45 study funder, patients, investigators, and study site
staff were masked to treatment assignment.
46 Participants and study
staff were masked to treatment assignment.
47 envelopes and patients, their families, and all trial
staff were masked to treatment assignment.
48 ors, steering committee members, and the study
statistician were masked to treatment assignment.
49 study personnel, except for pharmacists and
statisticians,
were masked to treatment assignment.
50 estigators, participants' families, and data analysis
teams were masked to treatment assignment.